Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance

Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.

Authors

M Aragri¹, M Milana², V C Di Maio¹, I Lenci², L Carioti¹, C F Perno³, V Svicher¹, M Angelico², F Ceccherini-Silberstein⁴

Affiliations

¹ Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
² Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.
³ Department of Oncology and Oncohematology, University of Milan, Milan, Italy.
⁴ Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. Electronic address: [email protected].

PMID: 32240711
DOI: 10.1016/j.cmi.2020.03.022

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aminoisobutyric Acids / therapeutic use*
Antiviral Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Cyclopropanes / therapeutic use*
Drug Therapy, Combination
Genotype
Hepacivirus / drug effects
Hepacivirus / genetics*
Hepatitis C / diagnosis
Hepatitis C / drug therapy*
Hepatitis C / virology
Humans
Lactams, Macrocyclic / therapeutic use*
Leucine / analogs & derivatives*
Leucine / therapeutic use
Male
Middle Aged
Proline / analogs & derivatives*
Proline / therapeutic use
Pyrrolidines
Quinoxalines / therapeutic use*
Sofosbuvir / therapeutic use*
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Aminoisobutyric Acids
Antiviral Agents
Benzimidazoles
Cyclopropanes
Lactams, Macrocyclic
Pyrrolidines
Quinoxalines
Sulfonamides
pibrentasvir
Proline
Leucine
glecaprevir
Sofosbuvir